Amy Conrad

Professional at Juniper Point, Inc.

Amy Conrad

Amy Conrad

Professional at Juniper Point, Inc.

Overview
RelSci Relationships

90

Number of Boards

1

Contact Data
Trying to get in touch with Amy Conrad? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Amy Conrad likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at SENTÉ, Inc. (California)

Relationship likelihood: Strong

President-San Diego Chapter at National Investor Relations Institute

Relationship likelihood: Strong

Vice President, Alere Investor Relations at Alere, Inc.

Relationship likelihood: Strong

Former Director-Investor Relations at Momenta Pharmaceuticals, Inc.

Relationship likelihood: Strong

Vice President of Corporate Development at KCD PR

Relationship likelihood: Strong

Executive Director at Centennial Communications Corp.

Relationship likelihood: Strong

Vice President, Investor Relations & Corporate Communications at Kura Oncology, Inc.

Relationship likelihood: Strong

Managing Director at Canale Communications, Inc.

Relationship likelihood: Strong

Senior Director, Investor Relations at Entropic Communications Inc.

Relationship likelihood: Strong

Managing Director at Westwicke Partners LLC

Relationship likelihood: Strong

Paths to Amy Conrad
Potential Connections via
Relationship Science
You
Amy Conrad
Professional at Juniper Point, Inc.
Career History
Professional
Current
Senior Director, Investor Relations & Corporate Communications
Prior - 2016

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Head-Investor Relations
Prior

Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ.

Boards & Committees
Co-President, Board of Directors
2015 - Current
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Amy Conrad. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Amy Conrad's profile does not indicate a business or promotional relationship of any kind between RelSci and Amy Conrad.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/amy-conrad-4518544
  • https://relationshipscience.com/person/amy-conrad-4518544